Amplify Weight Loss Drug & Treatment ETF (THNR)

Assets	$3.11M
Expense Ratio	0.59%
PE Ratio	25.21
Shares Out	130,000
Dividend (ttm)	$0.22
Dividend Yield	0.93%
Ex-Dividend Date	Dec 30, 2024
Payout Ratio	23.54%
1-Year Return	-9.16%

Volume	1,810
Open	23.63
Previous Close	23.55
Day's Range	23.41 - 23.63
52-Week Low	18.56
52-Week High	28.19
Beta	n/a
Holdings	27
Inception Date	May 21, 2024

About THNR

Fund Home Page

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.

• Asset Class: Equity
• Category: Health
• Region: Global
• Stock Exchange: NYSEARCA
• Ticker Symbol: THNR
• ETF Provider: Amplify Investments
• Index Tracked: VettaFi Weight Loss Drug Index

Top 10 Holdings

71.21% of assets

Name	Symbol	Weight
Novo Nordisk A/S	NVO	14.76%
Eli Lilly and Company	LLY	14.01%
Innovent Biologics, Inc.	1801	7.62%
Hims & Hers Health, Inc.	HIMS	6.48%
Chugai Pharmaceutical Co., Ltd.	4519	5.24%
Teva Pharmaceutical Industries Limited	TEVA	4.96%
West Pharmaceutical Services, Inc.	WST	4.63%
AstraZeneca PLC	AZN	4.53%
Roche Holding AG	ROG	4.51%
Pfizer Inc.	PFE	4.47%

Dividends

Ex-Dividend	Amount	Pay Date
Dec 30, 2024	$0.2199	Dec 31, 2024